Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Nocebo effect in myasthenia gravis: systematic review and meta-analysis of placebo-controlled clinical trials

Nocebo effect in myasthenia gravis: systematic review and meta-analysis of placebo-controlled... Nocebo refers to the adverse events (AEs) experienced when taking a placebo drug and is believed to be a centrally mediated process. We sought to examine the AEs following placebo administration in Randomised Controlled Trials (RCTs) for Myasthenia Gravis (MG) patients. A systematic literature search was performed on Medline and Web of Science for RCTs for MG pharmacological treatments. We assessed the number of placebo-treated patients reporting at least one AE and the number of dropouts because of AEs. Data were extracted from six RCTs fulfilling the search criteria. Four out of five placebo-treated participants (80.1%) reported at least one AE and one in 40 (2.4%) discontinued placebo treatment because of AE. All patients participating in the MG trials reported similar AEs independent of the study arm to which they belonged (placebo or active treatment). This meta-analysis demonstrates a low nocebo dropout rate in MG compared to central nervous system disorders. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Acta Neurologica Belgica Springer Journals

Nocebo effect in myasthenia gravis: systematic review and meta-analysis of placebo-controlled clinical trials

Varma, Adithya; Zis, Panagiotis
Acta Neurologica Belgica , Volume 119 (2) – Apr 19, 2019
Download PDF
8 pages

Loading next page...
 
/lp/springer-journals/nocebo-effect-in-myasthenia-gravis-systematic-review-and-meta-analysis-phhzCu0Nqw
Publisher
Springer Journals
Copyright
Copyright © 2019 by Belgian Neurological Society
Subject
Biomedicine; Neurosciences; Neurology; Neuroradiology; Medicine/Public Health, general
ISSN
0300-9009
eISSN
2240-2993
DOI
10.1007/s13760-019-01143-1
Publisher site
See Article on Publisher Site

Abstract

Nocebo refers to the adverse events (AEs) experienced when taking a placebo drug and is believed to be a centrally mediated process. We sought to examine the AEs following placebo administration in Randomised Controlled Trials (RCTs) for Myasthenia Gravis (MG) patients. A systematic literature search was performed on Medline and Web of Science for RCTs for MG pharmacological treatments. We assessed the number of placebo-treated patients reporting at least one AE and the number of dropouts because of AEs. Data were extracted from six RCTs fulfilling the search criteria. Four out of five placebo-treated participants (80.1%) reported at least one AE and one in 40 (2.4%) discontinued placebo treatment because of AE. All patients participating in the MG trials reported similar AEs independent of the study arm to which they belonged (placebo or active treatment). This meta-analysis demonstrates a low nocebo dropout rate in MG compared to central nervous system disorders.

Journal

Acta Neurologica Belgica – Springer Journals

Published: Apr 19, 2019

References

  • The nocebo effect and its relevance for clinical practice
    Colloca, L; Miller, FG
  • Nocebo in fibromyalgia: meta-analysis of placebo-controlled clinical trials and implications for practice
    Mitsikostas, DD; Chalarakis, NG; Mantonakis, LI; Delicha, EM; Sfikakis, PP
  • When words are painful: unraveling the mechanisms of the nocebo effect
    Benedetti, F; Lanotte, M; Lopiano, L; Colloca, L
  • Getting the pain you expect: mechanisms of placebo, nocebo and reappraisal effects in humans
    Tracey, I
  • Placebo and nocebo in interventional pain management: a friend or a foe–or simply foes?
    Manchikanti, L; Giordano, J; Fellows, B; Hirsch, JA
  • How positive and negative expectations shape the experience of visceral pain
    Elsenbruch, S
  • Nonspecific medication side effects and the nocebo phenomenon
    Barsky, AJ; Saintfort, R; Rogers, MP; Borus, JF
  • New insights into the placebo and nocebo responses
    Enck, P; Benedetti, F; Schedlowski, M
  • Nocebo in Alzheimer’s disease; meta-analysis of placebo-controlled clinical trials
    Zis, P; Mitsikostas, DD
  • Nocebo as a potential confounding factor in clinical trials for Parkinson’s disease treatment: a meta-analysis
    Stathis, P; Smpiliris, M; Konitsiotis, S; Mitsikostas, DD
  • Nocebo effects in multiple sclerosis trials: a meta-analysis
    Papadopoulos, D; Mitsikostas, DD
  • Nocebo in motor neuron disease: systematic review and meta-analysis of placebo-controlled clinical trials
    Shafiq, F; Mitsikostas, DD; Zis, P
  • Nocebo is the enemy, not placebo. A meta-analysis of reported side effects after placebo treatment in headaches
    Mitsikostas, DD; Mantonakis, LI; Chalarakis, NG
  • Nocebo in headaches: implications for clinical practice and trial design
    Mitsikostas, DD
  • Adverse events attributable to nocebo in randomized controlled drug trials in fibromyalgia syndrome and painful diabetic peripheral neuropathy: systematic review
    Hauser, W; Bartram, C; Bartram-Wunn, E; Tolle, T
  • A meta-analytic approach to estimating nocebo effects in neuropathic pain trials
    Papadopoulos, D; Mitsikostas, DD
  • Placebo and nocebo responses in restless legs syndrome: a systematic review and meta-analysis
    Silva, MA; Duarte, GS; Camara, R; Rodrigues, FB; Fernandes, RM; Abreu, D
  • Nocebo in clinical trials for depression: a meta-analysis
    Mitsikostas, DD; Mantonakis, L; Chalarakis, N
  • The role of patient expectancy in placebo and nocebo effects in antidepressant trials
    Rutherford, BR; Wall, MM; Glass, A; Stewart, JW
  • Nocebo effect in refractory partial epilepsy during pre-surgical monitoring: systematic review and meta-analysis of placebo-controlled clinical trials
    Zis, P; Shafiq, F; Mitsikostas, DD
  • Nocebo effect in Meniere’s disease: a meta-analysis of placebo-controlled randomized controlled trials
    Dimitriadis, PA; Zis, P
  • Nocebo in chronic inflammatory demyelinating polyneuropathy; a systematic review and meta-analysis of placebo-controlled clinical trials
    Zis, P; Hadjivassiliou, M; Sarrigiannis, PG; Jenkins, TM; Mitsikostas, DD
  • Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement
    Moher, D; Liberati, A; Tetzlaff, J; Altman, DG
  • Assessing the quality of reports of randomized clinical trials: is blinding necessary?
    Jadad, AR; Moore, RA; Carroll, D; Jenkinson, C; Reynolds, DJ; Gavaghan, DJ
  • Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study
    Howard, JF; Utsugisawa, K; Benatar, M; Murai, H; Barohn, RJ; Illa, I
  • Tacrolimus in the treatment of myasthenia gravis in patients with an inadequate response to glucocorticoid therapy: randomized, double-blind, placebo-controlled study conducted in China
    Zhou, L; Liu, W; Li, W; Li, H; Zhang, X; Shang, H
  • A randomized controlled trial of methotrexate for patients with generalized myasthenia gravis
    Pasnoor, M; He, J; Herbelin, L; Burns, TM; Nations, S; Bril, V
  • A double-blinded, randomized, placebo-controlled trial to evaluate efficacy, safety, and tolerability of single doses of tirasemtiv in patients with acetylcholine receptor-binding antibody-positive myasthenia gravis
    Sanders, DB; Rosenfeld, J; Dimachkie, MM; Meng, L; Malik, FI
  • Randomised, double-blind, placebo-controlled study of tacrolimus in myasthenia gravis
    Yoshikawa, H; Kiuchi, T; Saida, T; Takamori, M
  • An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis
    Sanders, DB; Hart, IK; Mantegazza, R; Shukla, SS; Siddiqi, ZA; Baets, MH
  • The biochemical and neuroendocrine bases of the hyperalgesic nocebo effect
    Benedetti, F; Amanzio, M; Vighetti, S; Asteggiano, G
  • The nocebo effect of drugs
    Planes, S; Villier, C; Mallaret, M
  • Adverse events and nocebo phenomena: treatment or disease specific?
    Zis, P; Sykioti, P
  • Safety, tolerability, and nocebo phenomena during transcranial magnetic stimulation: a systematic review and meta-analysis of placebo-controlled clinical trials
    Zis, P; Shafique, F; Hadjivassiliou, M; Blackburn, D; Venneri, A; Iliodromiti, S; Mitsikostas, DD; Sarrigiannis, PG
  • Nocebo responses in brain diseases: a systematic review of the current literature
    Zis, P; Mitsikostas, DD
  • The hierarchy of evidence: levels and grades of recommendation
    Petrisor, BA; Bhandari, M
  • To tell the truth, the whole truth, may do patients harm: the problem of the nocebo effect for informed consent
    Wells, RE; Kaptchuk, TJ